Bausch Health Companies Inc. Proceeds from Lines of Credit
Bausch Health Companies Inc. (BHC) reported Proceeds from Lines of Credit of $690.00 million for the 3-month period ending 2011-09-30, per its 10-Q filed 2011-11-04.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2012-02-29
- Bausch Health Companies Inc. proceeds from lines of credit for the quarter ending 2011-09-30 was $690.00M.
- Bausch Health Companies Inc. proceeds from lines of credit for the quarter ending 2011-06-30 was $100.00M.
- Bausch Health Companies Inc. proceeds from lines of credit for the quarter ending 2009-12-31 was $0.00.
- Bausch Health Companies Inc. proceeds from lines of credit for the quarter ending 2009-09-30 was $0.00.
- Bausch Health Companies Inc. proceeds from lines of credit for fiscal 2009 was $130.00M.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2011-09-30 | $690.00M 10-Q · filed 2011-11-04 | $790.00M derived: sum of 2 quarters · filed 2011-11-04 | $790.00M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $100.00M 10-Q · filed 2011-08-08 | $100.00M 10-Q · filed 2011-08-08 | ||
| 2009-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $0.00 derived: sum of 2 quarters · filed 2012-02-29 | $130.00M derived: sum of 3 quarters · filed 2012-02-29 | $130.00M 10-K · filed 2012-02-29 |
| 2009-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-05 | $130.00M derived: sum of 2 quarters · filed 2010-11-05 | $130.00M 10-Q · filed 2010-11-05 | |
| 2009-06-30 | $130.00M 10-Q · filed 2010-08-06 | $130.00M 10-Q · filed 2010-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |